Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 19669-19669
Author(s):  
M. K. Altundag ◽  
M. Dincer ◽  
H. Harputluoglu ◽  
S. Aksoy ◽  
Y. Ozisik ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Skeletal Complications ◽  
Few Data ◽  
Acid Administration ◽  
Renal Safety

19669 Background: Zoledronic acid (ZA) delays the onset or reduces the incidence of skeletal complications in breast cancer patients with bone metastases. However there are few data on the long-term renal safety of ZA. Methods: We retrospectively evaluated 43 breast cancer patients with bone metastases who received ZA more than 24 months. The following parameters measured prior to first ZA use and after the last dose of ZA administration were compared: serum creatinine (SCr), blood urea nitrogen (BUN), alkaline phosphatase (ALP), calcium (Ca), and phosphorous (P). Results: Forty-three breast cancer patients with documented bone metastases were evaluated. Median age at the start of treatment was 53 years (range, 37 to 77). Median overall duration of ZA administration was 36 months (25 to 62). There were no statistically significant differences in the pre- and post-treatment levels of SCr, BUN, Ca and P. However, ALP levels after long-term ZA administration were decreased significantly (P <0.05). Conclusion: More than 24 months of ZA administration did not adversely affect the renal function. ZA can be used safely in breast cancer patients with bone metastases beyond 2 years. [Table: see text] No significant financial relationships to disclose.

Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases

2008 ◽  
Vol 25 (3) ◽  
pp. 356-359 ◽  
Author(s):  
Murat Dincer ◽  
Kadri Altundag ◽  
Hakan Harputluoglu ◽  
Sercan Aksoy ◽  
Mustafa Cengiz ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Acid Administration ◽  
Renal Safety

Renal safety profile of ibandronate 6mg infused over 15 or 60 min in breast cancer patients with bone metastases

Bone ◽  
2008 ◽  
Vol 42 ◽  
pp. S107
Author(s):  
F. Schütz ◽  
R. von Moos ◽  
C.B. Caspar ◽  
R. Angst ◽  
R. Inauen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Safety Profile ◽  
Breast Cancer Patients ◽  
Renal Safety

Results of a prospective, randomized, double-blind, double-dummy, Phase 3 study comparing denosumab with zoledronic acid for the treatment of breast cancer patients with bone metastases

Bone ◽  
2010 ◽  
Vol 46 ◽  
pp. S36-S37 ◽  
Author(s):  
Jean-Jacques Body ◽  
Alison Stopeck ◽  
Yasuhiro Fujiwara ◽  
Allan Lipton ◽  
Guenther Steger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Phase 3 ◽  
Double Blind

Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy

2006 ◽  
Vol 24 (30) ◽  
pp. 4895-4900 ◽  
Author(s):  
Mark J. Clemons ◽  
George Dranitsaris ◽  
Wei S. Ooi ◽  
Geetha Yogendran ◽  
Tatjana Sukovic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Turnover ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Pain Control ◽  
Second Line ◽  
Breast Cancer Patients ◽  
First Line ◽  
The Impact

Purpose This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate. Patients and Methods This prospective study evaluated the impact of second-line zoledronic acid on pain, quality of life, and markers of bone turnover (for example, urinary N-telopeptide [NTX]). Patients received monthly zoledronic acid (4mg) for 3 months. Study evaluations were made weekly during the first month and again at week 8. No changes in chemotherapy or endocrine therapy were allowed in the month before or after commencing study treatment. Results Thirty-one women completed this study. By week 8, patients had experienced significant improvements in pain control (P < .001). There was a downward trend in urinary NTX levels over the same time period (P = .008). Overall, there was a trend towards a positive correlation between improvement in pain control and reduction in week one urinary NTX relative to baseline (Spearman's rho r = 0.27; P = .15). Conclusion This is the first study to demonstrate that patients with either progressive bone metastases or SREs while on clodronate or pamidronate can have relevant palliative benefits with a switch to the more potent bisphosphonate zoledronic acid. This is reflected by significant improvements in pain control and bone turnover markers. If confirmed in randomized trials, these findings have major implications to the use of bisphosphonates in both the metastatic and adjuvant settings.

Effect of adherence to monthly zoledronic acid treatment on risk and frequency of skeletal complications and follow-up duration in breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 9593-9593
Author(s):  
H. T. Hatoum ◽  
S. Lin ◽  
M. R. Smith ◽  
A. Lipton
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Cancer Patients ◽  
Lower Risk ◽  
Propensity Scores ◽  
Female Breast Cancer ◽  
Breast Cancer Patients ◽  
Skeletal Complications ◽  
Comorbidity Index

9593 Background: Bone is the most common site of metastasis in breast cancer patients (pts). Clinical trials and outcome studies have demonstrated benefit of zoledronic acid (ZA) in reducing risk of skeletal complications (SC). This study explored relationships between persistency on ZA and the intended treatment (TX) outcomes. Methods: Female breast cancer pts with first bone metastasis (BM) diagnosed between Jan 03 to Oct 06 were identified from PharMetrics database. Persistency was defined as duration from initiating ZA TX to date of first TX gap of >45 days. Pts were divided into short (≤90 days, 230 pts), medium (91–180, 171 pts) and long (>180, 313 pts) persistency groups. TX selection bias was handled by calculating propensity scores using year of first BM diagnosis, having other metastases or >1 BM claim, use of opioids and oral bisphoshonate before BM. Propensity scores, age and Charlson's Comorbidity Index (CCI) were included in multiple regressions to investigate impact of ZA persistency on follow-up duration, risk and rate of SC. Results: 2394 pts were enrolled, with 714 (29.72%) ZA treated. Three persistency groups had similar age. Short group had higher CCI than long group (mean 8.53 vs 8.34, p<0.05). Frequency of ZA TX decreased over time in all groups. For short, medium and long persistency groups, means of follow-up durations were 9.8 (median, 7.0), 13.0 (9.0), 19.3 (18.1) months, and means of time to first SC after BM were 249 (median: 167), 323 (217), 418 (365) days. Means of SC rates were 0.27, 0.21, and 0.12 per month for patients who experienced at least 1 SC among the three groups. Medium and long persistency groups had 41% and 139% longer follow-up than short group (p<0.05). Long group had lower risk of SC than short group (HR=0.576, p<0.05). In patients who developed at least 1 SC, long group experienced 39% less SCs (p<0.005) than short group. Conclusions: TX with zoledronic acid in breast cancer pts with BM positively impacts the risk, frequency of SC and follow-up duration. Also, longer persistency on ZA TX is associated with significantly longer follow-up and lower risk of SC. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document